Dr. Terry D. Heiman-Patterson, MD

Dr. Heiman-Patterson practices at Temple University Hospital - Main Campus in Philadelphia, Pennsylvania.

Dr. Heiman-Patterson's NPI, 1437100559, was assigned on May 13, 2006. Dr. Heiman-Patterson graduated from Albany Medical College of Union University in 1975. Dr. Heiman-Patterson holds Pennsylvania license MD021242E.

Dr. Heiman-Patterson's primary practice is Temple University Hospital - Main Campus, at 3401-41 N Broad St, Philadelphia, PA 19140 in Philadelphia County. The practice phone is (215) 707-5303.

Dr. Heiman-Patterson's primary practice is Temple University Hospital - Main Campus in Philadelphia, Pennsylvania. Dr. Heiman-Patterson is also affiliated with Temple University Hospital. The medical group on file is Temple Faculty Physicians. Dmand AI also links Dr. Heiman-Patterson to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Heiman-Patterson practices, 7 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Heiman-Patterson's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Heiman-Patterson is licensed in Pennsylvania.

CMS data shows 372 Medicare services from Dr. Heiman-Patterson across 6 procedure codes in 2024, for 147 Medicare patients. Medicare paid $29,055 for them.

CMS counts 147 Medicare patients who saw Dr. Heiman-Patterson in 2024. The largest group is under 65, with 69 patients. 66% of them have high blood pressure, and 66% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Heiman-Patterson's median patient age at 66, with 54% women.

In 2024, Dr. Heiman-Patterson wrote 2,003 Medicare Part D claims for 156 patients. 68% of them were for generic drugs. CMS names the drug for 1,712 of them, across 47 drugs with 11 or more claims each, at $10,363,624 in total drug cost. In 2023, CMS named 2,264 claims across 54 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Heiman-Patterson for performance year 2024, reported as part of a group. Dr. Heiman-Patterson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Heiman-Patterson as offering telehealth.

Dmand AI links 48 papers to Dr. Heiman-Patterson, published from 2011 to 2025. 2025 was the busiest year, with 8. The most frequent topics are Amyotrophic Lateral Sclerosis, Disease Models, Animal and Mice, Transgenic. Dr. Heiman-Patterson has published most often in Amyotroph Lateral Scler Frontotemporal Degener. Dr. Heiman-Patterson's most frequent co-authors are Carlayne E. Jackson, MD, Jinsy Andrews, MD and Merit Ester Cudkowicz, MD.

Dmand AI links Dr. Heiman-Patterson to 5 clinical trials. Conditions studied include Amyotrophic Lateral Sclerosis, TDP-43 Proteinopathies and Motor Neuron Disease. Drexel University College of Medicine sponsors the most, 2.

CMS Open Payments shows 133 general payments to Dr. Heiman-Patterson from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Mitsubishi Tanabe Pharma America, Inc. paid the most, $37,076. It also lists 1 research payment totaling $2,800 in 2022.

Dr. Heiman-Patterson graduated from Albany Medical College of Union University in 1975.